Targeting human T-cell metabolism for modulating immune function requires an understanding 38 of macronutrient utilization. Using metabolic inhibition during activation of human naïve CD8 + 39 T-cells, we demonstrate blocking glycolysis or mitochondrial respiration prevents T-cell 40 proliferation. However, after activation and differentiation, the metabolic program changes. 41 Inhibition of glycolysis abolished cytotoxic T-lymphocyte (CTL) activity, whereas mitochondrial 42 inhibition had no effect on CTL lytic function. Studies with uniformly labeled 13 C-glucose 43 confirmed CTL convert the majority of glucose to lactate. The role of glycolysis in CTL function 44 was assessed using NOD models of Type 1 diabetes (T1D). Treatment of NOD models with a 45 glycolysis inhibitor resulted in reduced and delayed T1D incidence and significantly preserved 46 β-cell mass. We conclude glycolysis and mitochondrial ATP production are essential for 47 efficient T-cell activation, but only glycolysis is essential for CTL lytic function. These data 48 suggest targeting glycolysis in CTLs is a promising pathway to prevent T-cell-mediated 49 autoimmunity. 50 51 52
During co-culture with target cells CTL favor the conversion of glucose to lactate versus
glutamate. 214 215 Next, we determined the utilization of glucose in CTLs using 13 C-NMR. IGRP-GFP CD8 + T-216 cells were co-cultured for 16 hours with βlox5 cells in the presence of uniformly labeled 13 C 217 glucose or 13 C galactose with and without 2DG. Collected samples were analyzed for the 218 formation and amount of 13 C-lactate and 13 C-glutamate produced using jHSQC NMR 12 . 219 Analysis revealed that CTLs produce more lactate compared to glutamate (40% compared to 220 15%, Figure 5a ) in the presence of βlox5 cells. There was a reduction in lactate and glutamate 221 production when galactose was the sole energy substrate; however, CTLs still continued to 222 produce more lactate than glutamate (Figure 5b) . The addition of 2DG reduced both the 223 amount of lactate and glutamate produced in both uniformly labeled glucose and galactose 224 conditions, which was indicated by the absence of 13 C-glutamate peaks in the jHSQC and 1 D 225 projection analyses (Figure 5c ). Ultimately, activated and expanded CTLs break down glucose 226 via glycolysis, shuttle this to lactate formation, and do not drive mitochondrial respiration as 227 indicated by reduced glutamate labeling. Glutamate effectively reads out substrate selection for 228 acetyl-CoA production 13 . 229 230 2DG delays diabetes onset in NOD/ShiLtJ and NOD.AI4 α/β-Thy1 α/b mice. 231 232 In light of these data, we sought to understand CTL metabolism in vivo using a T1D model 233 where metabolic activity of CD8 + T-cell destruction of pancreatic beta cells could be studied. 234 10-week-old female NOD/ShiLtJ mice were placed onto water bottles that contained either 235 filter-sterilized water alone or water containing 35mM 2DG over a 20-week follow-up period. 236 Diabetes incidence was monitored via tail vein blood glucose assessment, with a statistically 237 significant increase in the survival of the 2DG treated mice compared to control water mice. An 238 additional group of 10-week-old female NOD/ShiLtJ mice were treated with 35mM 2DG in their 239 drinking water for 10 weeks and subsequently removed; diabetes incidence was monitored, 240 with the majority of mice succumbing to diabetes after the removal of 2DG (Figure 6a) . In insulin-specific CD8 + T-cells were placed onto water bottles that contained either filter-sterilized 243 water alone or water containing 35mM 2DG at 3 weeks of age. Spontaneous diabetes 244 incidence was monitored every other day via tail vein blood glucose assessment. There was a 245 marked delay in diabetes onset by 9 days in treated mice compared to control water mice 246 (Figure 7a) . 247 After determining that 35mM 2DG delayed the onset of diabetes, we wanted to determine 248 whether 35mM 2DG treated NOD.AI4 mice had insulin preservation within the islets compared 249 to that of the control. Analysis revealed a statistically significant retention (p=0.0023) of insulin 250 positivity in 2DG treated mice (Figure 7b) . Additionally, there was no difference in the amount 251 of CD3 positive cells within the pancreatic sections of 35mM 2DG treated NOD.AI4 ( Figure   252 7c). These data clearly show, and correlate with the above human data, that CD8 + T-cells are 253 able to migrate and traffic into the pancreas, but are unable to illicit effector functionality, thus 254 preserving insulin producing beta cells.
256
Upon diabetes onset, mice were euthanized; spleens were harvested from NOD/ShiLtJ mice, 257 and peripheral blood, pancreatic lymph nodes, and spleens were harvested from NOD.AI4 (Figure 6f and 6g) . Total CD8 + T-cells (Figure 7d-7f) , as well as naïve, 266 memory, or effector phenotypes, were also analyzed ( Figure S2 ) from NOD.AI4 mice. There 267 were no differences displayed in the naïve, memory, or effector populations of NOD.AI4 268 specific CD8 + T-cells treated with 35mM 2DG compared to the control mice.
270
With a greater effect seen in the NOD/ShiLtJ mice compared to the NOD.AI4 mice, we wanted 271 to determine if increasing the concentration of 2DG in the drinking water of mice would alter 272 the outcome in the NOD.AI4 model. We treated starting at 3-weeks of age NOD.AI4 mice with 273 70mM 2DG and monitored for them for spontaneous diabetes onset. The delay in diabetes 274 onset was drastically significant when increasing the amount of 2DG, with NOD.AI4 mice 275 surviving out to 37 ± 11 days (p<0.0001). However, there was no significant difference in the 
Diabetogenic NOD.AI4 CD8 + T-cells can proliferate in 2DG treated mice.

283
With 70mM 2DG significantly delaying the onset of diabetes incidence, we investigated the 284 ability of the NOD.AI4 CD8 + T-cells to proliferate in 70mM 2DG treated mice. Starting at 6-285 weeks of age NOD/ShiLtJ mice were treated with 70mM 2DG in their drinking water or 286 received filter-sterilized water for 2 weeks prior to receiving a sublethal 750R irradiation dose.
287
After irradiation, 3-week-old NOD.AI4 splenocytes were stained with a cell tracking dye, Cell 288 Trace Violet (CTV), and injected into the tail vein of the control and treated NOD/ShiLtJ mice.
289
After 3 days, peripheral blood and pancreatic lymph nodes (PLN) were harvested from the 290 control and 2DG NOD/ShiLtJ mice, and AI4 CD8 + T-cells were assessed for the presence of 291 CTV. The isolated AI4 tetramer + cells contained no non-diluted proliferation dye, indicating that 292 these cells can proliferate in the presence of 70mM 2DG, with further analyses revealing that 293 there was no difference between the control and treated NOD.AI4 CD8 + T-cells expression of 294 Ki67 or cells present in the PLN (Figure 7j-7l) . 295 296 To further test that 2DG treated cells are able to confer disease, splenocytes were isolated 297 from 2DG treated and untreated NOD/ShiLtJ mice and adoptively transferred into lymphocyte 298 deficient NOD.CB17-Prkdc scid /J recipients, and diabetes incidence was monitored (Figure 6b) . 299 The adoptive transfer of splenocytes from 2DG treated NOD/ShiLtJ mice were able to confer mouse T-cell subsets in comparison to humans. Further investigation is warranted, but this 309 strengthens the need for more human studies to be carried out in T1D to ensure that we are 310 effectively understanding patient relevant in vivo phenotypes.
312 313
This study opens new areas of investigation on how CD8 + T-cells can be targeted to prevent 316 autoimmunity. Studies in disease models of lupus have previously shown that 2DG treatment 317 of mice reduced the biomarkers and disease-associated changes through normalization of T-318 cell metabolism 14 . In T1D, studies using murine models have indicated that T-cell 319 mitochondrial dysfunction may participate in the pathogenesis 15 . We have also more recently 320 discovered that T-cells from patients with T1D, exhibit mitochondrial inner membrane The enclosed investigations provide novel information by specifically looking at human CD8 + T- Research Resource Identification (RRID) numbers used in this study were: SAMN08912443.
353
Detailed islet donor information is outlined in Supplemental Table 1 .
355
Animals: All mice used in this study were housed in specific pathogen-free facilities. These Figure 4 . Two ATP from glycolysis is the bioenergetic requirement for CTL lytic function and not mitochondrial ATP production. βlox5 cells were primed with rhIFNγ (1000 IU/mL) for 24 hours. a) Cells were then co-cultured with IGRP-specific CD8 + T cells in varying concentrations of glucose or galactose for 16 hours. Specific lysis was determined using the cell mediated killing assay (CML) b) βlox5 cells were co-cultured with IGRP-specific CD8 + T cells in the presence of the glycolytic inhibitor 2DG, glycolytic substrate pyruvate and the mitochondrial electron transport chain complex II substrate, methylsuccinate, for 16 hours. c) βlox5 and IGRP-Specific CD8 + T cells were co-cultured in the presence of ATP translocase inhibitor, cATR, with either glucose or galactose. d) βlox5 and IGRP-Specific CD8 + T cells were co-cultured in the presence ETC complex I and III inhibitor, rotenone and antimycin A, and the complex II substrate methylsuccinate. e) βlox5 and IGRP-Specific CD8 + T cells were cocultured in 100% nitrogen (anoxic) conditions for 16 hours. f) IGRP-specific CD8 + T cells were co-cultured with βlox5 16 hours in 5.5mM Glucose or 2.7mM Glucose and 2.7mM 2DG. Supernatants and T cell pellets were harvested and Granzyme B levels determined. Mean ± SEM graphed. *** denotes p <0.001 and **** p<0.0001. These data are compiled from 5 healthy donors. 
Figure 5.
Reduced lactate and glutamate levels exhibited in the presence of U 13 C-Galactose and 2DG. βlox5 and CD8 + T cells were co-cultured at 30:1 in the presences of either U 13 C-Glucose, U 13 C-Galactose and 2DG a) U 13 Clabelled glutamate and lactate fractional enrichments were determined and analysed in T cell pellet and supernatants and combined. b) U 13 C-labelled glutamate and lactate concentrations were determined and analysed in T cell pellet and supernatants and combined. c) Representative jHSQC and 1 D projections showing 13 C labelling pattern for glutamate, acetate and lactate metabolites within T cell pellets that were labelled with U 13 C-Glucose d) Representative jHSQC and 1 D projections showing 13 C labelling pattern for glutamate, acetate and lactate metabolites within T cell pellets that were labelled with U 13 C-Glucose and 2DG. Glu-C4 represents C4 of glutamate and Lac-C3 denotes C3 of lactate. "S" and "D" denote singlet and doublet formations. c. Figure 6 . 2DG administered in vivo delays the on-set of spontaneous diabetes in NOD/shiLtJ and NOD.AI4αβ mice. a) 10-week old female NOD/shiLtJ mice were treated with 35mM 2DG in their drinking water for 20 weeks and diabetes incidence monitored with a statistically significant increase in survival of the 2DG treated mice compared to control water mice. Red-dashed line indicates 10-week old female NOD/shiLtJ mice that were treated with 35mM 2DG in their drinking water for 10 weeks which was subsequently removed and diabetes incidence monitored. b) Splenocytes from 2DG treated or untreated NOD/ShiLtJ mice were adoptively transferred into NOD.CB17-Prkdcscid/J mice and incidence monitored post transfer. c-e) Total CD4 + and CD8 + T cells, CD4 + Tregs and B cells and follicular B cells were analysed in NOD/ShiLtJ mice that were placed onto regular drinking water, treated water with 35mM 2DG or treated for 10 weeks with 2DG and were placed back onto regular water. f-g) CD73 + Breg and non-B cells, and marginal zone B, T1 and T2 B cell subsets were analysed in NOD/ShiLtJ mice that were placed onto regular drinking water, treated water with 35mM 2DG or treated for 10 weeks with 2DG and were placed back onto regular water. i. j. k.
l. Figure 7 . 2DG administered in vivo delays the on-set of spontaneous diabetes but does not alter total CD8 + T cell numbers or halt proliferation in NOD.AI4αβ mice. a) 3-week old NOD.AI4αβ mice were treated with 35mM and 70mM 2DG in their drinking water and incidence of diabetes monitored until mice reached a blood glucose level of >600mg/dL on two consecutive days. Analysis revealed a statistically significant increase in the delay of diabetes onset in 70mM 2DG treated mice compared to that of untreated mice. b) Weekly cheek bleeds were carried out and total CD8 + T cells monitored in control and 35mM treated mice until diabetes on-set was reached. c-d) Upon reaching diabetes on-set mice were sacrificed and total CD8+ T cells analysed in the spleen and pancreatic lymph node respectively. e) Image analysis was carried out to determine total insulin positive staining in pancreatic sections in control and 2DG NOD.AI4αβ mice. Analysis revealed a statistically significant increase in insulin positive islets compared to control. f) Image analysis was carried out to determine total CD3 positive staining in pancreatic sections in control and 2DG NOD.AI4αβ mice. Analysis revealed no statistically significant difference in CD3 positive cells compared to that of control mice. g) Weekly cheek bleeds were carried out and total CD8 + T cells monitored in control and 70mM treated mice until diabetes on-set was reached. h-i) Upon reaching diabetes on-set mice were sacrificed and total CD8+ T cells analysed in the spleen and pancreatic lymph node respectively. j) Pancreatic lymph nodes from sub-lethally irradiated 70mM treated NOD/ShiLtJ were removed 3 days post injection with CTV labeled NOD.AI4αβ splenocytes and Ai4 tetramer + cells analysed for Ki67 expression. k) Live Ai4 tetramer + cells were analysed with no difference observed in treated mice pancreatic lymph nodes compared to that of control mice. l) No difference was observed in cellular numbers obtained from the pancreatic lymph nodes of 70mM treated mice compared to control mice. Mean ± SD graphed.
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